About this trial
This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black men with newly diagnosed prostate cancer. Cancer is the second leading cause of death for African American/Black men, with prostate cancer leading in estimated new cancer cases and second in estimated new cancer deaths. Over 40,000 African American/Black men are diagnosed with prostate cancer annually, with 1 in 6 lifetime probability of developing prostate cancer compared to 1 in 8 probability in White men. The PPCD ViRA provides psycho-oncology support, social determinants of health navigation and emotional support for ethnically diverse African American/Black men newly diagnosed with prostate cancer using artificial intelligence and augmented reality. Using PPCD ViRA may close the prostate cancer care gap for African American/Black men across the cancer continuum and provide emotional, educational, and resource needs of this population when they are visiting a doctor about their prostate health or prostate cancer.
Eligibility criteria
Qualifiers
African American/Black male
Diagnosed with CaP within two months
Be a patient at a participating clinic or affiliates with one of our community sites
Consent to participating in the study
Disqualifiers
Do not speak or understand English
Unable to read or write
Trial design
Treatments tested in this trial
- Best Practice
- Discussion
- Survey Administration
- Virtual Reality
Treatment groups
Sponsors and collaborators
Mayo Clinic
Lead sponsor
Congressionally Directed Medical Research Programs
Collaborator